The results of this study extend previous patient-level analyses showing that two or more of the three biochemical hallmarks of CKD-MBD, PTH, calcium, and phosphate, out of or above the target ranges established by KDOQI or Kidney Disease: Improving Global Outcomes (KDIGO) strongly predicts the risk of major clinical outcomes, independent of case-mix and baseline comorbidity [2, 3, 7]. This evidence concerns the gene PTH and chronic kidney disease.